Abstract
Objectives
To evaluate and compare the clinical implications of common inflammatory markers in systemic rheumatic diseases (SRDs).
Method
We investigated the profiles of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and white blood cell (WBC) count in treatment-naïve patients with SRDs, osteoarthritis and pneumonia diagnosed at Seoul National University Hospital during 2004–2016. SRDs included rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), ankylosing spondylitis (AS), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM) and adult-onset Still’s disease (AOSD). Associations between inflammatory markers were evaluated using Pearson’s correlation and regression analysis. ROC curve analysis was performed to examine the predictive value of inflammatory markers for SRD diagnosis.
Results
We identified a total of 1191 patients. Leukocytosis was present in < 20% SRD patients. There was marked variability in ESR and CRP levels among different SRDs. The highest mean CRP levels (mean ± SD, mg/dL) were observed in AOSD (11.3 ± 7.9), followed by RA (2.0 ± 3.3), IIM (1.8 ± 3.5), SLE (1.5 ± 3.1), SSc (0.6 ± 1.3) and AS (0.08 ± 0.1). Mean ESR (mm/h) was also highest in AOSD (71.2 ± 31.0), followed by SLE (47.3 ± 34.2), RA (45.5 ± 30.6), IIM (40.8 ± 24.8) and SSc (27.8 ± 26.0). All SRDs showed significant positive correlations between ESR and CRP: greatest in RA (r = 0.53, p < 0.001) and weakest in SLE (r = 0.20, p = 0.03). WBC correlated weakly with CRP but not with ESR in most SRDs. While the AUC for WBC count was less than that of ESR or CRP, the AUC for ESR and CRP were similar in SRD. The optimal cuff-off values for inflammatory markers predicting SRD were within or slightly above the normal limit.
Conclusions
ESR, CRP and WBC are not always elevated in treatment-naïve patients with SRD. Individual SRDs have a unique profile of inflammatory markers. However, routine inflammatory markers should still be interpreted with caution when diagnosing and assessing disease activity in those with SRD.
Key Points •Leukocytosis and elevation of ESR and CRP are not always present in all systemic rheumatic diseases. •Inflammatory markers are often dissociated and they are not specific for disease diagnosis. •Better biomarkers, which measure disease-specific local and systemic inflammation, are needed. |
Similar content being viewed by others
Data availability
The data that support the results of this study are available from the corresponding author, JKP, upon request.
References
Zweifach BW, Grant L, McCluskey RT (2014) The inflammatory process. Academic Press, New York
Gruys E, Toussaint M, Niewold T, Koopmans S (2005) Acute phase reaction and acute phase proteins. J Zhejiang Univ Sci B 6:1045–1056
Heinrich PC, Castell JV, Andus T (1990) Interleukin-6 and the acute phase response. Biochem J 265:621–636
Feldman M, Aziz B, Kang GN, Opondo MA, Belz RK, Sellers C (2013) C-reactive protein and erythrocyte sedimentation rate discordance: frequency and causes in adults. Transl Res 161:37–43
Keenan R, Swearingen C, Yazici Y (2008) Erythrocyte sedimentation rate and C-reactive protein levels are poorly correlated with clinical measures of disease activity in rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis patients. Clin Exp Rheumatol 26:814–819
Syed KM, Pinals RS (1996) Leukocytosis in rheumatoid arthritis. J Clin Rheumatol 2:197–202
Go DJ, Lee EY, Lee EB, Song YW, Konig MF, Park JK (2016) Elevated erythrocyte sedimentation rate is predictive of interstitial lung disease and mortality in dermatomyositis: a Korean retrospective cohort study. J Korean Med Sci 31:389–396. https://doi.org/10.3346/jkms.2016.31.3.389
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725–1725
Linden SVD, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. Arthritis Rheum 27:361–368
Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA, Carreira PE (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum 65:2737–2747
Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, Kashiwazaki S, Tanimoto K, Matsumoto Y, Ota T (1992) Preliminary criteria for classification of adult Still’s disease. J Rheumatol 19:424–430
Bohan A, Peter JB (1975) Polymyositis and dermatomyositis. N Engl J Med 292:344–347
Siemons L, ten Klooster PM, Vonkeman HE, van Riel PL, Glas CA, van de Laar MA (2014) How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis. BMC Musculoskelet Disord 15:368
Lakoski SG, Cushman M, Criqui M, Rundek T, Blumenthal RS, D'Agostino RB Jr, Herrington DM (2006) Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J 152:593–598
Ranganath VK, Elashoff DA, Khanna D, Park G, Peter JB, Paulus HE (2005) Age adjustment corrects for apparent differences in erythrocyte sedimentation rate and C-reactive protein values at the onset of seropositive rheumatoid arthritis in younger and older patients. J Rheumatol 32:1040–1042
Isaacs A, Lindenmann J (1957) Virus interference. I. The interferon. Pro R Soc Lond B Biol Sci 147:258–267
Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD (1998) How cells respond to interferons. Annu Rev Biochem 67:227–264
Dinarello CA (2000) Proinflammatory cytokines. Chest 118:503–508
Pinsky MR, Vincent J-L, Deviere J, Alegre M, Kahn RJ, Dupont E (1993) Serum cytokine levels in human septic shock: relation to multiple-system organ failure and mortality. Chest 103:565–575
Holub M, Lawrence DA, Andersen N, Davidová A, Beran O, Marešová V, Chalupa P (2013) Cytokines and chemokines as biomarkers of community-acquired bacterial infection. Mediat Inflamm 2013:190145. https://doi.org/10.1155/2013/190145
McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A (2015) Type I interferons in infectious disease. Nat Rev Immunol 15:87–103. https://doi.org/10.1038/nri3787
O'Shea JJ, Ma A, Lipsky P (2002) Cytokines and autoimmunity. Nat Rev Immunol 2:37
Maria AT, Le Quellec A, Jorgensen C, Touitou I, Riviere S, Guilpain P (2014) Adult onset Still’s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev 13:1149–1159. https://doi.org/10.1016/j.autrev.2014.08.032
Schett G, Elewaut D, McInnes IB, Dayer J-M, Neurath MF (2013) How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med 19:822–824
Moulis G, Sommet A, Lapeyre-Mestre M, Montastruc J-L (2014) Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database. Rheumatology 53:1864–1871. https://doi.org/10.1093/rheumatology/keu214
Gaitonde S, Samols D, Kushner I (2008) C-reactive protein and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 59:1814–1820
Honig S, Gorevic P, Weissmann G (1977) C-reactive protein in systemic lupus erythematosus. Arthritis Rheum 20:1065–1070
Becker G, Waldburger M, Hughes G, Pepys M (1980) Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. Ann Rheum Dis 39:50–52
Hill AS (1951) C-reactive protein in the chronic rheumatic diseases. Lancet 2:807–811
Aringer M (2019) Inflammatory markers in systemic lupus erythematosus. J Autoimmun. https://doi.org/10.1016/j.jaut.2019.102374
Greenberg SA (2010) Type 1 interferons and myositis. Arthritis Res Ther 12:1–7. https://doi.org/10.1186/ar2885
Greenberg SA (2010) Dermatomyositis and type 1 interferons. Curr Rheumatol Rep 12:198–203. https://doi.org/10.1007/s11926-010-0101-6
Salajegheh M, Kong SW, Pinkus JL, Walsh RJ, Liao A, Nazareno R, Amato AA, Krastins B, Morehouse C, Higgs BW, Jallal B, Yao Y, Sarracino DA, Parker KC, Greenberg SA (2010) Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 67:53–63. https://doi.org/10.1002/ana.21805
Park JK, Gelber AC, George M, Danoff SK, Qubti MA, Christopher-Stine L (2013) Pulmonary impairment, not muscle injury, is associated with elevated ESR in the idiopathic inflammatory myopathies. Rheumatology (Oxford) 52:1336–1338. https://doi.org/10.1093/rheumatology/ket162
Gupta P, Friberg LE, Karlsson MO, Krishnaswami S, French J (2010) A semi-mechanistic model of CP-690,550-induced reduction in neutrophil counts in patients with rheumatoid arthritis. J Clin Pharmacol 50:679–687
Tanaka Y, McInnes IB, Taylor PC, Byers NL, Chen L, de Bono S, Issa M, Macias WL, Rogai V, Rooney TP (2018) Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis. Arthritis Rheum 70:1923–1932
Smith E, Jorgensen A, Beresford M (2017) Do classic blood biomarkers of JSLE identify active lupus nephritis? Evidence from the UK JSLE cohort study. Lupus 26:1212–1217
Schäfer VS, Weiß K, Krause A, Schmidt WA (2018) Does erythrocyte sedimentation rate reflect and discriminate flare from infection in systemic lupus erythematosus? Correlation with clinical and laboratory parameters of disease activity. Clin Rheumatol 37:1835–1844
Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA (2018) Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis 77:840–847
Muangchan C, Harding S, Khimdas S, Bonner A, Group CSR, Baron M, Pope J (2012) Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. Arthritis Care Res (Hoboken) 64:1405–1414
Yayla ME, İlgen U, Okatan İE, UsluYurteri E, Torgutalp M, Dinçer ABK, Gülöksüz EGA, Sezer S, Turgay TM, Kınıklı G (2020) Association of simple hematological parameters with disease manifestations, activity, and severity in patients with systemic sclerosis. Clin Rheumatol 39:77–8
Author information
Authors and Affiliations
Contributions
JKP conceived and designed the study. MJK acquired the data, did statistical analysis and drafted the manuscript. All authors interpreted the data, critically revised the manuscript for important intellectual content and approved the final version of the manuscript.
Corresponding author
Ethics declarations
Disclosures
None.
Ethics approval
The study complied with the Declaration of Helsinki and was approved by the Institutional Review Board of Seoul National University Hospital (H-1702-064-831).
Consent to participate
The requirement for informed consent was waived due to the retrospective nature of study.
Consent to publication
Not applicable
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM1
(DOCX 16 kb)
Rights and permissions
About this article
Cite this article
Kim, M.J., Lee, E.B., Song, Y.W. et al. Profile of common inflammatory markers in treatment-naïve patients with systemic rheumatic diseases. Clin Rheumatol 39, 2899–2906 (2020). https://doi.org/10.1007/s10067-020-05049-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-020-05049-9